PHASE II STUDY ON TREATMENT WITH VELCADE, DEXAMETHASONE AND FOTEMUSTINE IN PATIENTS AFFECTED BY RELAPSED/REFRACTORY MULTIPLE MYELOMA

Trial Profile

PHASE II STUDY ON TREATMENT WITH VELCADE, DEXAMETHASONE AND FOTEMUSTINE IN PATIENTS AFFECTED BY RELAPSED/REFRACTORY MULTIPLE MYELOMA

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2013

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Fotemustine (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms B-MUD
  • Most Recent Events

    • 28 Jun 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 08 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top